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Abstract
Background: The endocannabinoid system (ECS) is a ubiquitously expressed signalling system, with involvement
in lipid metabolism and obesity. There are reported changes in obesity of blood concentrations of the
endocannabinoids anandamide (AEA) and 2-arachidonoylglcyerol (2-AG), and of adipose tissue expression levels of
the two key catabolic enzymes of the ECS, fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL).
Surprisingly, however, the activities of these enzymes have not been assayed in conditions of increasing adiposity.
The aim of the current study was to investigate whether FAAH and MGL activities in human subcutaneous
adipocytes are affected by body mass index (BMI), or other markers of adiposity and metabolism.
Methods: Subcutaneous abdominal mature adipocytes, fasting blood samples and anthropometric measurements
were obtained from 28 metabolically healthy subjects representing a range of BMIs. FAAH and MGL activities were
assayed in mature adipocytes using radiolabelled substrates. Serum glucose, insulin and adipokines were
determined using ELISAs.
Results: MGL activity showed no relationship with BMI or other adiposity indices, metabolic markers (fasting serum
insulin or glucose) or serum adipokine levels (adiponectin, leptin or resistin). In contrast, FAAH activity in
subcutaneous adipocytes correlated positively with BMI and waist circumference, but not with skinfold thickness,
metabolic markers or serum adipokine levels.
Conclusions: In this study, novel evidence is provided that FAAH activity in subcutaneous mature adipocytes
increases with BMI, whereas MGL activity does not. These findings support the hypothesis that some components
of the ECS are upregulated with increasing adiposity in humans, and that AEA and 2-AG may be regulated
differently.
Keywords: Endocannabinoid system, Fatty acid amide hydrolase, Monoacylglycerol lipase, Human, Adipocytes, BMI,
Insulin, Glucose
Introduction
The endocannabinoid system (ECS) is expressed in most
human tissues and comprises the endocannabinoids,
their receptors and the enzymes required for their
synthesis and degradation. The two best characterised
endocannabinoids are N-arachidonoylethanolamide
(anandamide, AEA) [1] and 2-arachidonoylglycerol (2-
AG) [2,3]. Fatty acid amide hydrolase (FAAH) is respon-
sible for the majority of AEA hydrolysis and also
accounts for a minor amount of 2-AG inactivation [4,5],
but this is predominantly catalysed by monoacylglycerol
lipase (MGL) [4].
The ECS is present in human adipocytes [6], although
relatively little is understood of its role in adipose tissue.
Both AEA and 2-AG have been identified in isolated
adipocytes from human visceral adipose tissue [7], while
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synthesise both endocannabinoids [8]. It has also been
demonstrated, in a murine preadipocyte cell line, that
induction of adipogenesis leads to a significant increase
in intracellular levels of AEA and 2-AG, and that 2-AG
concentrations remain high in mature adipocytes [7,9].
In addition, AEA has been shown to induce differentia-
tion of murine preadipocytes, possibly by direct activa-
tion of PPARg [10]. With regard to the expression of
ECS-related enzymes, mature adipocytes contain higher
levels of FAAH mRNA than preadipocytes [11], indicat-
ing that the ECS may have an important role in func-
tional adipocytes. A role for the ECS in human
adipocytes is further supported by the presence of the
two major endocannabinoid receptors, CB1 and CB2
[12]. However, the precise role of the ECS in adipocytes
is still a matter for investigation (for review see [13]).
It has been suggested that overall ECS tone is
increased in human obesity on the basis that reports of
plasma levels of AEA [11,14] and 2-AG [15] correlate
positively with BMI. Circulating 2-AG levels correlate
with waist circumference [11] and more in depth analy-
sis has shown that the most significant rise in 2-AG
occurs in those with visceral obesity [14,15]. Addition-
ally, weight loss in obese men has been shown to reduce
plasma levels of both AEA and 2-AG [16]. However, the
relative expression levels of components of the ECS in
adipose tissue in obese compared to lean humans have
yet to be confirmed.
Levels of FAAH mRNA expression in human adipose
tissue have been measured by multiple laboratories and
conflicting findings have been reported. In some studies,
FAAH mRNA is reported to be higher in the subcuta-
neous adipose tissue of obese compared to lean subjects
[17,18], whereas other studies report FAAH mRNA to
be decreased [11,14,19]. According to one study, hyper-
insulinaemia increased FAAH mRNA in the subcuta-
neous abdominal adipose tissue in lean, but not in
obese, subjects leading the authors to suggest that the
chronic hyperinsulinaemia often present in obese
humans could contribute to FAAH upregulation in adi-
pose tissue [18]. There are no obvious reasons as to why
discrepancies have been reported with regard to FAAH
expression levels in adipose tissue in obesity. The tech-
niques used in these studies appear to have been similar,
as do the subjects sampled, although females are repre-
sented more than males in the studies showing FAAH
to be downregulated in obesity, and males are a larger
proportion of the results showing FAAH to be upregu-
lated. A further connection between FAAH and obesity
has been identified via a missense mutation in the
FAAH gene, which occurs in 3.6-10.8% of the popula-
tion (depending on ethnicity) and is associated with obe-
sity [20].
Most of the above studies have compared lean and
obese subjects, and all have reported mRNA levels of
FAAH without reference to final protein levels or activ-
ity. To the best of our knowledge, to date, there is only
one published study on the enzyme activity of FAAH in
human adipose tissue, and this was performed only to
confirm its presence [21]. In order to increase our
understanding of the role of FAAH in human adipo-
cytes, and whether this alters with BMI, it is important
to investigate FAAH activity, and thus endocannabinoid
degradation, in isolated adipocytes.
MGL expression in human adipose tissue has not yet
been extensively investigated with regard to obesity. In
one study, MGL mRNA in omental and subcutaneous
adipose tissue was compared between distinct cohorts
of lean and obese humans and it was found that in
omental adipose, MGL mRNA was decreased with obe-
sity, but that obesity had no effect on MGL expression
in abdominal subcutaneous adipose tissue [19]. How-
ever, in another study, MGL mRNA was found to be
upregulated in the abdominal subcutaneous and omen-
tal adipose tissue of obese subjects [17]. Knowing
that plasma 2-AG is particularly increased in obesity
[15], and the speculation that 2-AG secretion from adi-
pocytes may contribute to this, it is important to
establish the effects of obesity on MGL activity in
adipocytes.
The current study was therefore designed to investi-
gate the activity of FAAH and MGL in adipocytes taken
from healthy human volunteers representing a continu-
ous range of BMIs from normal to obese. Assays were
undertaken in mature adipocytes isolated from human
subcutaneous adipose tissue to exclude interference
from other cells in adipose tissue such as preadipocytes
or immune cells (other studies measured enzyme
expression in the entire adipose tissue sample
[11,14,17-19,21]). In addition, a number of obesity-
related physical and metabolic parameters were investi-
gated. The primary aim of the study was to investigate
the effects of BMI on FAAH and MGL activity in
human adipocytes. A secondary objective was to exam-
ine whether a relationship exists between these enzyme
activities and various measures of adiposity and
metabolism.
Materials and methods
Subjects
The study was approved by the University of Notting-
ham Medical School Ethics Committee. 28 volunteers
were recruited from within the University of Notting-
ham. Written informed consent was obtained and exclu-
sion criteria included smoking, hypertension and known
metabolic disease. All subjects reported a stable weight
in the three month period preceding the biopsy.
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Blood pressure was measured with subjects rested and
in the supine position. Waist circumference was mea-
sured at the midpoint between the iliac crest and costal
margin, and hip circumference was taken at the widest
point around the hips. Neck circumference was mea-
sured at the level of the cricothyroid cartilage and arm
circumference was measured at the midpoint between
the shoulder and elbow. Skinfold thickness was mea-
sured using Harpenden calipers at the following anato-
mical sites: tricep, bicep, subscapular, iliac crest,
abdominal, chest and midaxilla [22]. The values
obtained from each were summed to give an indication
of the amount of subcutaneous body fat for each
subject.
Adipose and blood sampling
Subjects were asked to fast for at least 12 hours prior to
the adipose tissue biopsy. The subcutaneous abdominal
adipose biopsies were aspirated using a needle under
local anaesthetic with 1% lidocaine. Venous blood sam-
ples were obtained and serum was separated and stored
at -80°C.
Isolation and homogenisation of mature adipocytes
The method used to obtain mature adipocytes was
adapted from that described by Rodbell [23]. The adi-
pose samples were immediately added to an equal
volume of type II collagenase in phosphate buffered sal-
ine (PBS; 1 mg.ml
-1; Sigma-Aldrich, UK) and allowed to
digest at 37°C for 45 minutes. The samples were then
washed twice in PBS using centrifugation (500 × g,2
minutes) to separate the mature adipocytes which
formed a floating layer. The isolated adipocytes were
stored at -80°C until homogenisation.
Cells were homogenised in TE buffer (50 mM Tris, 1
mM EDTA, pH 7.4) using a hand-held glass homogeni-
ser on ice. The homogenates were centrifuged (18,000 ×
g, 10 minutes) and the supernatant layer then removed
and spun again (20,000 × g, 30 minutes). The superna-
tant layer from this step was then stored at -80°C as the
cytosolic fraction. The cellular pellet was homogenised
in PBS (10 mM phosphate, 2.7 mM potassium chloride,
137 mM sodium chloride, pH 7.4), centrifuged (20,000
× g, 30 minutes), re-suspended and stored at -80°C.
Enzyme activity assays
Enzyme assays were conducted essentially as described
by Boldrup et al., 2004 [24]. In brief, the particulate
fraction of the adipocyte homogenates was assayed in
duplicate for FAAH activity. Sample aliquots were
diluted in TE buffer containing fatty acid free albumin
at 1 mg.ml
-1 (pH 7.4) and pre-incubated at 37°C for 10
minutes with the FAAH inhibitor URB597 (1 μM, Sigma
Chemical Company, UK), or vehicle. [
3H]-AEA (2 μM,
American Radiolabelled Chemicals, USA) was added
and the samples were incubated at 37°C for 30 minutes.
Activated charcoal (2 volumes, 10% w/v in 0.5 M HCl)
was used to stop the reaction. After brief centrifugation,
an aliquot of each supernatant layer was taken for scin-
tillation counting. Tubes without homogenate were run
in parallel and used to establish blank values. In all
cases, activity in the presence of URB597 was no differ-
ent from blanks.
The cytosolic fraction of the adipocyte homogenates
was assayed in duplicate for MGL activity using a simi-
lar method as above, substituting a MGL inhibitor,
methylarachidonylfluorophosphonate (MAFP, 1 μM,
Sigma Chemical Company, UK), and 2-oleoyl-[
3H]-gly-
cerol (2-OG, 100 μM, American Radiolabelled Chemi-
cals, USA). In this assay the samples were incubated at
37°C for 15 minutes. In all cases, activity in the presence
of MAFP was no different from blanks.
Blood serum analysis
Aliquots of blood serum were thawed immediately
p r i o rt ot e s t i n g ,a n dg l u c ose and insulin assays were
performed within 6 months of sample collection.
Serum glucose concentrations were determined using
the YSI 2300 STAT PLUS glucose and lactate analyser
(YSI Life Sciences, USA). Insulin concentrations of the
serum samples were measured using a commercially
available ELISA kit (Mercodia, Sweden). The homeo-
static model assessment (HOMA2-%S) figures were
calculated using the HOMA2 model (http://www.dtu.
ox.ac.uk). Plasma adiponectin, leptin and resistin con-
centrations were measured within 18 months of sample
collection via commercially available sandwich ELISAs
(DuoSets from R&D, USA). All samples were tested in
duplicate.
Statistical analysis
GraphPad Prism (California, USA) software was used to
analyse all of the data, using linear regression to report
the Pearson correlation coefficient.
Results
Subject demographics
The results of this study were obtained from metaboli-
cally healthy humans ranging in BMI from 19.1-33.8 kg.
m
-2. Physiological data of these subjects are given in
Table 1. All subjects had a fasting blood glucose con-
centration of < 5.6 mmol.L
-1 on the day of biopsy. Cor-
relation studies confirmed that subjects reported in this
study follow well-documented findings in the literature;
for example, BMI correlated with MAP (r
2 =0 . 2 2 ,P <
0.05), waist (r
2 =0 . 6 9 ,P < 0.001), and the sum of the
skinfold thicknesses (r
2 = 0.39, P < 0.001).
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In these metabolically healthy subjects, MGL activity in
subcutaneous mature adipocytes did not correlate with
BMI (r
2 = 0.04, P = 0.32; Figure 1B), the sum of all 7
skinfold thicknesses (r
2 <0 . 0 1 ,P = 0.66; Figure 1D) or
with skinfold thickness at each individual site measured
(see Table 2). In contrast, FAAH activity in subcuta-
neous mature adipocytes correlated positively with BMI
(r
2 =0 . 1 4 ,P = 0.047; Figure 1A). The sum of the skin-
fold thicknesses did not correlate with FAAH activity (r
2
= 0.09, P = 0.11; Figure 1C). There was similarly no cor-
relation between FAAH activity and any of the indivi-
dual skinfold thicknesses measured (Table 2) with
FAAH activity.
Endocannabinoid-metabolising enzyme activities and
circumferences
FAAH activity was found to correlate positively with
waist circumference (r
2 =0 . 1 8 ,P =0 . 0 2 3 ;F i g u r e2 A ) .
FAAH activity showed a trend towards a positive corre-
lation (all P < 0.1) with hip circumference (r
2 =0 . 1 0 ,P
= 0.094; Figure 2C), neck circumference (r
2 = 0.13, P =
0.055; Figure 2E) and arm circumference (r
2 = 0.11, P =
0.080; Figure 2G). In contrast, MGL activity did not
correlate with waist circumference (r
2 <0 . 0 1 ,P =0 . 7 1 ;
Figure 2B), hip circumference (r
2 =0 . 0 2 ,P =0 . 5 0 ;F i g -
ure 2D), neck circumference (r
2 =0 . 0 6 ,P =0 . 2 1 ;F i g u r e
2F) or arm circumference (r
2 = 0.07, P = 0.18; Figure
2H).
Endocannabinoid-metabolising enzyme activities and
glycaemic markers
Although the subjects included in this study were con-
sidered metabolically healthy, there was a range of fast-
ing serum glucose (4.4-5.6 mmol.L
-1) and insulin (12.5-
91.0 pmol.L
-1) values. Neither fasting insulin (r
2 < 0.01,
P = 0.72; Figure 3A) nor glucose (r
2 = 0.05, P =0 . 2 7 ;
Figure 3C) showed any relationship with FAAH activity
in mature abdominal subcutaneous adipocytes. This was
also true for HOMA2-%S (r
2 < 0.01, P = 0.78). Similarly,
MGL activity did not correlate with fasting serum con-
centrations of insulin (r
2 <0 . 0 1 ,P =0 . 8 2 ;F i g u r e3 B ) ,
glucose (r
2 =0 . 0 1 ,P = 0.61; Figure 3D), or with
HOMA2-%S (r
2 = 0.01, P = 0.56).
Endocannabinoid-metabolising enzyme activities and
serum adipokines
Fasting serum concentrations of adiponectin (r
2 = 0.02,
P = 0.48; Figure 4A), leptin (r
2 =0 . 0 3 ,P =0 . 4 1 ;F i g u r e
4C) and resistin (r
2 = 0.04, P = 0.298; Figure 4E) did not
correlate with FAAH activity in subcutaneous adipo-
cytes. MGL activity also failed to correlate with fasting
serum concentrations of adiponectin (r
2 <0 . 0 1 ,P =
0 . 6 5 ;F i g u r e4 B ) ,l e p t i n( r
2 =0 . 0 2 ,P =0 . 4 4 ;F i g u r e4 D )
or resistin (r
2 < 0.01, P = 0.68; Figure 4F).
Discussion
The principal aim of the current study was to investigate
whether the activities of FAAH and MGL, two key cata-
bolic enzymes of the ECS, are altered with increasing
BMI. In measuring the activities of the enzymes, rather
than mRNA, we are able to present novel data that
FAAH activity in human subcutaneous mature adipo-
cytes increases with BMI and waist circumference. In
contrast there is no relationship between MGL activity
and BMI or the other adiposity markers measured.
Neither FAAH nor MGL activity correlates with fasting
serum concentrations of insulin, glucose or various adi-
pokines in these healthy volunteers.
In several published studies, FAAH mRNA levels in
adipose tissue have been compared between lean and
obese humans, and there is conflict over whether FAAH
is up- or down-regulated in adipose tissue in obesity
[11,14,17-19]. In order to investigate this further, we
measured FAAH activity in our population, as mRNA
levels do not always accurately reflect final protein levels
[25]. We found that in the abdominal subcutaneous
mature adipocytes of metabolically healthy people,
Table 1 Anthropometric and physiological data of study
subjects
Male:female 14:14
Age
(years)
20-48
31 ± 8.7
BMI
(kg.m
-2)
19.1-33.8
24.2 ± 3.4
Systolic blood pressure
(mmHg)
104-135
120.5 ± 8.8
Diastolic blood pressure
(mmHg)
60-91
73.4 ± 7.2
Mean arterial pressure
(mmHg)
77-106
89.1 ± 6.2
Waist circumference
(cm)
69-114
82.2 ± 10.7
Sum of 7-point skinfolds
(mm)
63-173
99.9 ± 25.5
Fasting serum glucose
(mmol.L
-1)
4.4-5.6
5.1 ± 0.3
Fasting serum insulin
(pmol.L
-1)
12.5-91.0
40.3 ± 21.9
HOMA2-%S 59.4-361.5
165.0 ± 79.2
Serum adiponectin
(μg.ml
-1)
3.55-21.28
10.93 ± 5.0
Serum leptin
(ng.ml
-1)
0.34-36.53
8.5 ± 15.4
Serum resistin
(ng.ml
-1)
5.38-32.07
11.49 ± 7.2
Data are expressed as range, and as mean ± S.D. BMI, body mass index;
HOMA2-%S, homeostatic model assessment for insulin sensitivity.
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ence. This finding is in agreement with studies showing
increased FAAH mRNA in the subcutaneous adipose of
obese individuals compared to lean [17,18], but at odds
with others [11,14,19]. The reasons for the apparently
discrepant results are currently unclear, but two of these
studies used entirely female samples [11,19], and the
other studied surgical patients [14]. It should also be
n o t e dt h a to u rr e s u l t sa r en o tn e c e s s a r i l yd i r e c t l yc o m -
parable to previous findings, given that previous studies
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Figure 1 FAAH and MGL activities in abdominal subcutaneous adipocytes with relation to BMI (A and B) and the sum of skinfold
thicknesses at 7 sites (C and D). Analysed using linear regression.
Table 2 Correlation studies between FAAH and MGL activities in subcutaneous adipocytes and skinfold thickness at
various sites (Pearson correlation coefficients)
Tricep Bicep Abdominal Iliac crest Subscapular Chest Midaxilla
FAAH r
2 < 0.01 0.04 0.11 0.06 0.08 0.08 0.12
activity P 0.76 0.33 0.09 0.20 0.14 0.14 0.07
MGL r
2 0.02 0.01 0.03 < 0.01 0.02 < 0.01 0.04
activity P 0.53 0.59 0.43 0.88 0.50 0.97 0.34
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Page 5 of 9have used whole adipose tissue homogenates and we
have specifically studied mature adipocytes. This is
important when considering the ECS in a metabolic
context, as mature adipocytes are the adipose cells
involved in energy homeostasis, but mature adipocytes
account for only half of the cells in adipose tissue. In
particular, it has been shown that macrophages have sig-
nificant FAAH expression [26]. In addition to this, we
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Figure 2 FAAH and MGL activities in abdominal subcutaneous adipocytes and circumferences of the waist (A and B), hip (C and D),
neck (E and F) and arm (G and H). Analysed using linear regression.
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BMIs in this study, as opposed to the discrete cohorts of
lean and obese subjects used in many studies. This has
allowed the inclusion of data on people with a BMI
between 25 and 30, which is a group that has not been
described previously. The increase of FAAH activity
with BMI that we observed may be metabolically protec-
tive, as missense mutations in the FAAH gene have
been associated with an unfavourable metabolic profile
in obese subjects [27].
The ECS is involved in the regulation of metabolism
and feeding in many human tissues, and some of its
components, particularly CB1,A E Aa n d2 - A G ,h a v e
been found to be upregulated in obesity [28,29]. An
increase in FAAH activity in adipocytes with increasing
BMI may simply be part of this general upregulation of
ECS tone in obesity. If both the synthesis and degrada-
tion of endocannabinoids are upregulated similarly, this
combination would not be predicted to affect endocan-
nabinoid signalling and the functional effects of endo-
cannabinoids within the adipocyte. This hypothesis is
supported by the recent finding that AEA levels in sub-
cutaneous adipose tissue are not different between lean
and non-diabetic obese humans [30]. Alternatively,
FAAH may be upregulated in isolation. This could
reduce AEA signalling at CB1 and CB2 receptors, and at
intracellular targets such as TRPV1 and PPARs, poten-
tially reducing CB1 mediated glucose uptake, lipogenesis
and adipogenesis [13].
It is known that in humans of the same BMI, visceral
adipose tissue accumulation confers greater metabolic
and cardiovascular risk than excess subcutaneous adi-
pose tissue [31]. With this in mind, we measured skin-
fold thickness at various anatomical sites to give an
indication of fat distribution in the subjects studied. In
addition to the correlation between FAAH activity and
waist circumference, we found a non-significant positive
relationship with hip circumference, neck circumference
and two central skinfold thicknesses (abdominal and
midaxillary), but not with the two peripheral skinfolds
measured (bicep and tricep). This is in keeping with
results showing that visceral obesity is a better predictor
of circulating 2-AG levels than non-specific obesity [14]
and may support the notion that central adipose accu-
mulation is more significant in relation to the ECS than
the amount of subcutaneous adipose tissue.
In one study showing chronic FAAH upregulation in
the subcutaneous adipose tissue of obese humans, it was
suggested that hyperinsulinaemia may cause this upre-
gulation, as similarly high FAAH expression was
induced in healthy lean humans using the euglycaemic
hyperinsulinaemic clamp method [18]. Considering this,
we investigated FAAH activity in comparison with fast-
ing serum levels of insulin and glucose, and HOMA2-%
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Figure 3 FAAH and MGL activities in abdominal subcutaneous
adipocytes and blood concentrations of insulin (A and B) and
glucose (C and D) in fasted subjects. Analysed using linear
regression.
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Figure 4 FAAH and MGL activities in abdominal subcutaneous
adipocytes and blood concentrations of adiponectin (A and B),
leptin (C and D) and resistin (E and F) in fasted subjects.
Analysed using linear regression.
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healthy volunteers, there was no correlation between
FAAH activity in subcutaneous adipocytes and fasting
serum concentrations of glucose or insulin, or HOMA2-
%S, although it should be noted that all subjects had
fasting serum levels of these parameters within normal
ranges. In order to investigate further a relationship
between insulin or glucose levels and FAAH activity in
adipocytes, further studies need to be conducted to
include subjects with poor glycaemic control.
Serum adipokine levels are known to be dysregulated
in obesity, with downregulation of adiponectin and
upregulation of leptin and resistin. As yet, few in vivo
studies have investigated adipokine levels with regard to
the ECS. We found that in healthy humans, FAAH
activity in adipocytes is not correlated with fasting
serum concentrations of adiponectin, leptin or resistin.
It has been shown that a FAAH missense mutation is
associated with both lower serum adiponectin concen-
trations in diabetic patients [32], and higher serum lep-
tin levels after weight loss in obese humans [27],
although the systemic nature of the mutation makes it
unclear as to the extent of adipocyte involvement in
these changes. In vitro, leptin has been shown to
increase FAAH activity in T lymphocytes [33], although
not in neuroblastoma cells [34], and our results suggest
that in vivo leptin does not significantly affect FAAH
activity in adipocytes.
MGL has a primary role in lipid metabolism, specifi-
cally in the hydrolysis of monoacylglycerols to release
glycerol and fatty acids that are subsequently trans-
ported out of the adipocyte. This explains the relatively
high activity of MGL (~300 fold) compared to FAAH
found in mature adipocytes in this study. The effects of
MGL activity on 2-AG signalling are substantial, as
demonstrated recently in mouse models, showing that
both systemic MGL inhibition and MGL gene deletion
lead to increased 2-AG levels in the brain and peripheral
tissues, and desensitisation of brain CB1 receptors
[35,36]. As MGL is not thought to be under hormonal
control in triglyceride catabolism, it has not been exten-
sively investigated in relation to obesity. However, given
the importance of MGL in 2-AG signalling in the ECS,
and considering that plasma 2-AG rises with obesity, we
investigated whether MGL activity changes with BMI or
other markers of adiposity. In contrast to our observa-
tions with FAAH activity, we found that MGL activity
in subcutaneous adipocytes has no relationship with
BMI, adiposity, serum adipokine levels or glycaemic reg-
ulation. This is in agreement with studies showing that
MGL mRNA levels in subcutaneous adipose tissue are
not different between lean and obese humans [19] and
intracellular 2-AG levels are increased in hypertrophic
adipocytes [7]. More generally, our findings are in
agreement with the observation that the rate of glycerol
release from adipose tissue is the same in lean and
obese subjects, in both fasting and fed states [37]. Our
findings suggest that, with regard to adipocyte contribu-
tion to generalised 2-AG catabolism, the increase in cir-
culating 2-AG observed in obese humans may be due to
enhanced production rather than decreased degradation.
In conclusion, the results of this study provide novel
evidence that FAAH activity, and thus the rate of endo-
cannabinoid degradation, in human subcutaneous
mature adipocytes from healthy humans increases with
BMI and waist circumference, but not with other mar-
kers of adiposity or metabolism. Conversely, MGL activ-
ity does not correlate with BMI or any other markers
measured in this study. These findings support the
hypothesis that some components of the ECS are upre-
gulated with increasing adiposity in humans.
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